|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
22,090,000 |
Market
Cap: |
293.13(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$8.84 - $22.64 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile roGen Pharma is a biopharmaceutical company focused on developing and commercializing solutions that treat urothelial and specialty cancers. Co.'s approved product Jelmyto® (mitomycin) for pyelocalyceal solution, and its investigational candidate, UGN-102 (mitomycin) for intravesical solution, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer, respectively. In addition, Co.'s immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
12,000 |
29,564 |
33,364 |
41,023 |
Total Sell Value |
$168,600 |
$445,409 |
$513,847 |
$580,710 |
Total People Sold |
1 |
2 |
2 |
2 |
Total Sell Transactions |
1 |
5 |
6 |
11 |
End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Schoenberg Mark |
Chief Medical OfficerOfficer |
|
2019-01-01 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
12,986 |
|
- |
|
Belldegrun Arie |
Director |
|
2019-01-01 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
114,211 |
|
- |
|
Schoenberg Mark |
Chief Medical OfficerOfficer |
|
2019-01-01 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
5,287 |
|
- |
|
Schreiber Alain |
10% Owner |
|
2017-11-28 |
4 |
S |
$40.51 |
$7,202,962 |
D/D |
(177,807) |
1,242,031 |
|
- |
|
Schreiber Alain |
10% Owner |
|
2017-11-27 |
4 |
S |
$41.12 |
$1,294,910 |
D/D |
(31,491) |
1,419,838 |
|
- |
|
Schreiber Alain |
10% Owner |
|
2017-05-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,451,329 |
|
- |
|
156 Records found
|
|
Page 7 of 7 |
|
|